Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Biotech
Health
STAT+
The Readout

CRISPR’s ancestors & big money for diabetes

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Nov. 30, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for November 30, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Medical device companies now need to prove to FDA…
Medical device companies now need to prove to FDA they’re protected against cyberattacks
Why medical school should start at age 28
Why medical school should start at age 28
Flawed herpes testing leads to many false positives —…
Flawed herpes testing leads to many false positives — and needless suffering
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories